Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of losmapimod to non-small cell lung cancer

A technology for non-small cell lung cancer and drug-resistant cells, which can be used in medical preparations containing active ingredients, respiratory diseases, organic active ingredients, etc., and can solve the problems of lack of further application and lack of research reports.

Active Publication Date: 2018-02-09
CHINA-US (HENAN) HORMEL CANCER INST
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most of these inhibitors failed to exert long-term efficacy in clinical phase I or II trials, which led to the lack of possibility of further application
As for the relationship between Losmapimod and non-small cell carcinoma, there is still a lack of in-depth and detailed research reports.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of losmapimod to non-small cell lung cancer
  • Application of losmapimod to non-small cell lung cancer
  • Application of losmapimod to non-small cell lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] This example mainly introduces the relationship between the p38 phosphorylation activation pathway and the production of tetraploid cells, as well as the relationship between Losmapimod and tetraploid cells. The related experiments are briefly introduced as follows.

[0048] Before introducing the specific experiments, some detection methods and experimental methods in the following experiments are briefly introduced as follows.

[0049] (1) Cell Viability Detection Method

[0050] When the cells are subcultured, digest the adherent cells with trypsin, resuspend the cells with the corresponding medium after centrifugation, adjust the cell concentration, and inoculate 3000 cells per well into a 96-well plate with a volume of 100 μL per well;

[0051] After 24 hours, add corresponding concentration of drug treatment (the drug is finally dissolved in 100 μL medium);

[0052] After 72 hours, add 20 μL of 0.3 mg / mL thiazolium blue (MTT, 3-(4,5-dimethylthiazole-2)-2,5-diphen...

Embodiment 2

[0086] Through the MTT cell activity detection experiment (refer to Example 1 for the experimental method) and the soft agar experiment, this example mainly tests the changes in the proliferation ability and clone formation ability of tumor cells after Losmapimod is used in combination with gefitinib. Before introducing the specific experiment, the soft agar experimental method is briefly introduced as follows.

[0087] experiment

[0088] Prepare 1.2% agarose, after autoclaving, place it in a 44°C water bath to keep the agarose in a melted state;

[0089] Prepare 2×1640, filter it with a 0.22 μm filter membrane into a sterilized container, and store it in a refrigerator at 4°C;

[0090] Prepare the lower layer glue, taking 50ml as an example: 20ml of 2×1640, 7.5ml of fetal bovine serum, 2.5ml of 1×PBS, 20ml of 1.25% agar, 5μL of gentamicin (50mg / ml), after preparation , placed in a 44°C water bath to keep warm;

[0091] Prepare 1640 medium with 15% FBS, taking 50 ml as an ...

Embodiment 3

[0105] On the basis of the above Examples 1 and 2, the inventors further carried out in vivo experiments on xenografted lung cancer mice resistant to gefitinib derived from patient tumor tissue (the tumor in this case was provided by Henan Cancer Hospital). The detailed experimental process The introduction is as follows.

[0106] The gefitinib-resistant non-small cell lung cancer tissue was inoculated subcutaneously into 40 mice, and the mice were divided into 4 groups (10 mice in each group); when the tumor volume in the mice was about 25mm 3 At that time, the four groups of mice were treated as follows:

[0107] 1. Control group (5% DMSO, 50% normal saline, 50% PEG400);

[0108] 2. 50mg / kg gefitinib treatment group;

[0109] 3. Losmapimod treatment group at 12 mg / kg;

[0110] 4. Co-treatment group of 50 mg / kg Gefitinib and 12 mg / kg Losmapimod (gastric administration);

[0111] Body weight and tumor volume (length × width) of the mice were measured twice a week 2 ×0.5)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention specifically relates to application of losmapimod to non-small cell lung cancer, belonging to the field of chemoprophylaxis of tumors. Losmapimod and a tyrosine kinase receptor inhibitorfor non-small cell lung cancer are combined and applied to non-small cell lung cancer, so tumor cells are enhanced in sensibility to the tyrosine kinase receptor inhibitor for non-small cell lung cancer, and formation of drug resistance is delayed. In the invention, it is proved for the first time that formation of gefitinib-resistant cell strains and gefitinib resistance is dependent on formation of tetraploid cells. When losmapimod and gefitinib are applied to tumor cells of non-small cell lung cancer together, tumor cells are obviously enhanced in sensibility to gefitinib, and multiplication and clone formation capabilities of tumor cells are inhibited; and thus, when gefitinib is applied to treatment of non-small cell lung cancer, the occurrence of gefitinib resistance is delayed, andthe application effect of gefitinib in treatment of non-small cell lung cancer is enhanced.

Description

technical field [0001] The present invention belongs to the field of tumor chemoprevention, and specifically relates to a patent application for the application of Losmapimod in non-small cell lung cancer. Background technique [0002] According to the latest World Health Organization (WHO) prediction report, lung cancer is the leading cause of death caused by cancer, and nearly 1.59 million people die of lung cancer worldwide. In China, the latest statistics on cancer statistics show that lung cancer has the highest incidence of cancer among men, and ranks second among women. Most importantly, lung cancer deaths have been the leading cause of cancer-related deaths since 2000. [0003] Non-small cell lung cancer is by far the most common type of lung cancer (accounting for about 80%), and the 5-year survival rate is only 15%. At present, chemotherapy is still one of the main treatments for lung cancer, but its effective rate is very low whether it is advanced lung cancer o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/455A61K31/5377A61P35/00A61P11/00
CPCA61K31/455A61K31/5377A61K2300/00
Inventor 董子钢杨耀韬刘康栋殷淑英
Owner CHINA-US (HENAN) HORMEL CANCER INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com